EZH2 expression is a prognostic factor in childhood intracranial ependymoma: A Canadian Pediatric Brain Tumor Consortium study

Cancer

Volumn 121, Issue 9, 2015, Pages 1499-1507

  Li, Amanda M ^a   Dunham, Christopher ^b   Tabori, Uri ^c   Carret, Anne Sophie ^d   McNeely, P Daniel ^e   Johnston, Donna ^f   Lafay Cousin, Lucie ^g   Wilson, Beverly ^h   Eisenstat, David D ⁱ   Jabado, Nada ^j   Zelcer, Shayna ^k   Silva, Mariana ^l   Scheinemann, Katrin ^m   Fryer, Christopher ^b   Hendson, Glenda ^b   Fotovati, Abbas ^a   Hawkins, Cynthia ^c   Yip, Stephen ⁿ   Dunn, Sandra E ^a   Hukin, Juliette ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e IWK HEALTH CENTRE   (Canada)

^f CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h STOLLERY CHILDREN S HOSPITAL   (Canada)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^k CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

^l QUEEN S UNIVERSITY   (Canada)

^m MCMASTER UNIVERSITY   (Canada)

ⁿ BRITISH COLUMBIA CANCER AGENCY   (Canada)

more..

Author keywords

AKT; brain; childhood; enhancer of zeste homolog 2; ependymoma; EZH2; protein kinase B

Indexed keywords

BMI1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN KINASE B; PROTEIN P16; TRANSCRIPTION FACTOR EZH2; Y BOX BINDING PROTEIN 1; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; TUMOR MARKER;

ADOLESCENT; AGE; ARTICLE; CANCER PROGNOSIS; CHILD; EPENDYMOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTERIOR FOSSA EPENDYMOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SUPRATENTORIAL EPENDYMOMA; TISSUE MICROARRAY; BRAIN TUMOR; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; EPENDYMOMA; FEMALE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84928303309     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29198     Document Type: Article

References (46)

1. Korshunov A, Golanov A, Timirgaz V,. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci. 2000; 177: 72-82.
2. Mansur DB, Perry A, Rajaram V, et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys. 2005; 61: 387-391.
3. Pollack IF, Gerszten PC, Martinez AJ, et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery. 1995; 37: 655-666; discussion 666-657.
4. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg. 1998; 88: 695-703.
5. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97-109.
6. Mack SC, Taylor MD,. The genetic and epigenetic basis of ependymoma. Childs Nerv Syst. 2009; 25: 1195-1201.
7. Witt H, Mack SC, Ryzhova M, et al. Delineation of 2 clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011; 20: 143-157.
8. Wani K, Armstrong TS, Vera-Bolanos E, et al. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol. 2012; 123: 727-738.
9. Purkait S, Jha P, Sharma MC, et al. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry. Neuropathology. 2013; 33: 405-412.
10. Kees UR, Burton PR, Lu C, Baker DL,. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood. 1997; 89: 4161-4166.
11. Quesnel B, Preudhomme C, Philippe N, et al. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood. 1995; 85: 657-663.
12. Korshunov A, Witt H, Hielscher T, et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol. 2010; 28: 3182-3190.
13. Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Mauro A, Schiffer D,. CDKN2A/p16 in ependymomas. J Neurooncol. 2001; 54: 9-13.
14. Godfraind C, Kaczmarska JM, Kocak M, et al. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol. 2012; 124: 247-257.
15. Modena P, Buttarelli FR, Miceli R, et al. Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis. Neuro Oncol. 2012; 14: 1346-1356.
16. Rousseau E, Ruchoux MM, Scaravilli F, et al. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol. 2003; 29: 574-583.
17. Viale G, Regan MM, Mastropasqua MG, et al. Predictive value of tumor Ki-67 expression in 2 randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst. 2008; 100: 207-212.
18. Preusser M, Heinzl H, Gelpi E, et al. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology. 2008; 53: 39-47.
19. Manasa LP, Uppin MS, Sundaram C,. Correlation of p53 and KI-67 expression with grade and subtype of ependymoma. Indian J Pathol Microbiol. 2012; 55: 308-313.
20. Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008; 40: 741-750.
21. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100: 11606-11611.
22. Knudsen ES, Dervishaj O, Kleer CG, Pajak T, Schwartz GF, Witkiewicz AK,. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer. Cell Cycle. 2013; 12: 2042-2050.
23. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419: 624-629.
24. Suva ML, Riggi N, Janiszewska M, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009; 69: 9211-9218.
25. Kim E, Kim M, Woo DH, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013; 23: 839-852.
26. Alimova I, Birks DK, Harris PS, et al. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol. 2013; 15: 149-160.
27. Chen H, Tu SW, Hsieh JT,. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem. 2005; 280: 22437-22444.
28. Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 2012; 72: 3091-3104.
29. DeHaan RD, Kipp BR, Smyrk TC, Abraham SC, Roberts LR, Halling KC,. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Hum Pathol. 2007; 38: 491-499.
30. Sher F, Rossler R, Brouwer N, Balasubramaniyan V, Boddeke E, Copray S,. Differentiation of neural stem cells into oligodendrocytes: involvement of the polycomb group protein Ezh2. Stem Cells. 2008; 26: 2875-2883.
31. Natsume A, Ito M, Katsushima K, et al. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer Res. 2013; 73: 4559-4570.
32. Villa R, Pasini D, Gutierrez A, et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell. 2007; 11: 513-525.
33. Cha TL, Zhou BP, Xia W, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science. 2005; 310: 306-310.
34. Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR,. Adult ependymal tumors: prognosis and the MD Anderson Cancer Center experience. Neuro Oncol. 2010; 12: 862-870.
35. Phi JH, Wang KC, Park SH, et al. Pediatric infratentorial ependymoma: prognostic significance of anaplastic histology. J Neurooncol. 2012; 106: 619-626.
36. Badura S, Tesanovic T, Pfeifer H, et al. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia [serial online]. PLoS One. 2013; 8: e80070.
37. Chapuis N, Tamburini J, Green AS, et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res. 2010; 16: 5424-5435.
38. Fouladi M, Perentesis JP, Phillips CL, et al. A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study. Pediatr Blood Cancer. 2014; 61: 1246-1251.
39. Okabe S, Tauchi T, Tanaka Y, et al. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Cancer Biol Ther. 2014; 15: 207-215.
40. Johnson RA, Wright KD, Poppleton H, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature. 2010; 466: 632-636.
41. Mack SC, Witt H, Piro RM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014; 506: 445-450.
42. Miranda TB, Cortez CC, Yoo CB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther. 2009; 8: 1579-1588.
43. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012; 8: 890-896.
44. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492: 108-112.
45. Kikuchi J, Takashina T, Kinoshita I, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of nonsmall cell lung cancer cells. Lung Cancer. 2012; 78: 138-143.
46. Chen MY, Liao WS, Lu Z, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011; 117: 4424-4438.